Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
The Infectious Diseases Society of America (IDSA) has released updated COVID-19 treatment guidelines focused on the use of pre-exposure prophylaxis in immunocompromised patients (Clin Infect Dis 2024;78[7]:e250-e349).
The recommendation, which was released on Aug. 12, 2024, concerns pemivibart (Pemgarda, Invivyd), the only FDA-authorized pre-exposure prophylaxis for COVID-19, which was granted